Edoxaban approved for embolism prevention

Name: Edoxaban approved for embolism prevention
Creator: Kate Traynor
Keywords: 03 medical and health sciences, 0302 clinical medicine, 3. Good health

descriptionPublicationkeyboard_double_arrow_right Article 15 Feb 2015 English Publisher:Oxford University Press (OUP)Journal:American Journal of Health-System Pharmacy, volume 72, pages 258-258 (issn: 1079-2082, eissn: 1535-2900,

Authors: Kate Traynor;

doi: 10.2146/news150011

Edoxaban approved for embolism prevention

- Summary
- Metrics

Abstract

FDA and Daiichi Sankyo on January 8 announced the approval of edoxaban, an oral factor Xa inhibitor, to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation that is unrelated to a heart valve problem. The drug, which will be marketed as Savaysa, is also indicated for

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average